Oncolytics Biotech, Inc. (USA)  

(Public, NASDAQ:ONCY)   Watch this stock  
Find more results for ONCY
-0.040 (-5.26%)
Feb 27 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.69 - 0.80
52 week 0.40 - 2.07
Open 0.78
Vol / Avg. 2.56M/1.27M
Mkt cap 67.39M
P/E     -
Div/yield     -
EPS -0.19
Shares 93.51M
Beta 2.20
Inst. own 2%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -97.56% -93.57%
Return on average equity -119.37% -127.20%
Employees 25 -
CDP Score - -


210-1167 Kensington Cres NW
+1-403-6707377 (Phone)
+1-403-2830858 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Oncolytics Biotech Inc. (Oncolytics) is a Canada-based development-stage company. The Company is focused on the research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from reovirus. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions. The Company�s clinical trial program has included human trials using REOLYSIN alone, and in combination with radiation and chemotherapy, and delivered via local administration and/or intravenous administration. The Company has two subsidiaries: Oncolytics Biotech (Barbados) Inc. (OBB) and Valens Pharma Ltd.

Officers and directors

Bradley G. Thompson Ph.D. Executive Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Kirk J. Look Chief Financial Officer
Bio & Compensation  - Reuters
Matthew C. Coffey Ph.D. Chief Operating Officer, Director
Bio & Compensation  - Reuters
George M. Gill M.D. Senior Vice President - Regulatory Affairs & Chief Safety Officer
Bio & Compensation  - Reuters
Alan J. Tuchman M.D. Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs
Age: 67
Bio & Compensation  - Reuters
Mary Ann Dillahunty J.D. Vice President - Intellectual Property
Bio & Compensation  - Reuters
Robert B. Schultz Lead Independent Director
Bio & Compensation  - Reuters
James F. Dinning Independent Director
Age: 61
Bio & Compensation  - Reuters
Edwin Levy Ph.D. Independent Director
Bio & Compensation  - Reuters
J. Mark Lievonen Independent Director
Bio & Compensation  - Reuters